Efficacy and Safety of ChOline ALfoscerate in Patient With Mild to Moderate Alzheimer's Disease

Alzheimer Disease Clinical Trial

— COALA  

Official title:

A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase IV Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate in Patients With Mild to Moderate Alzheimer's Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05383183
• Other study ID #: DWB-CA400
• Status: Recruiting
• Phase: Phase 4
• Start date: January 20, 2022
• Est. completion date: December 9, 2025

Study information

• Verified date: March 2024
• Source: Daewoong Bio Inc.
• Contact: Yunjae Ahn
• Phone: +82-550-8191
• Email: yjahn[@]daewoong-bio.co.kr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether combination of donepezil, a cholinesterase inhibitor, with choline alfoscerate has a more favourable clinical profile than monotherapy with donepezil alone.

Description:

Aging population is a characteristic feature of demographic trends in developed countries. Hence, Alzheimer's disease is recognized as one of today's major healthcare challanges, and its significance will increase even more as the longevity of the population increases. Pre-clinical investigations have suggested that association between ChE-Is (cholinesterase inhibitors) and the cholinergic precursor choline alfoscerate enhances cholinergic neurotransmission more effectively than single compounds alone. This clinical trial is designed to assess if combination of the ChE-I donepezil with choline alfoscerate has a more favorable clinical profile than monotherapy with donepezil alone.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 630
• Est. completion date: December 9, 2025
• Est. primary completion date: June 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years to 85 Years

Eligibility

Inclusion Criteria:

<Screening Inclusion Criteria>

1. 50 = Age = 85 at time of screening

2. Diagnosed as a probable Alzheimer Dementia patient according to the NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association) criteria

3. 10 = K-MMSE-2 score = 26 at time of screening

4. 0.5 = CDR score = 2 at time of screening

5. Administration of donepezil 5 mg or 10 mg without dose change for at least 3 months at time of screening

6. Ability to walk or to move using a walking aid (i.e. senior walker, cane, or wheelchair)

7. Presence of a caregiver who regularly spends time with the patient and can accompany the patient to hospital visits

• The caregiver must spend at least 8 hours per week with the patient

• The caregiver should be able to supervise trial compliance and report subject status to the investigator

8. Sufficient visual acuity, hearing, language ability, motor function and comprehension, as judged by the investigator, to follow the examination procedure (auxiliary devices such as glasses and hearing aids are permitted)

9. Voluntarily decision to participate in this clinical trial from both the subject and the subject's legal representative

<Randomization Inclusion Criteria>

1. 10 = K-MMSE-2 score = 26 at time of randomization

2. Compliance with donepezil = 80% during run-in

Exclusion Criteria:

<Screening Exclusion Criteria>

1. Dementia due to other causes including:

• Probable vascular dementia according to NINDS-AIREN criteria

• Infection of the central nervous system (eg HIV, syphilis, etc.)

• Head trauma

• Creutzfeld-Jacob disease

• Pixie's disease

• Huntington's disease

• Parkinson's disease

• Drug addiction and/or Alcoholism

2. Patients with other major structural brain diseases (strategic cerebral infarction, subdural hematoma, traffic hydrocephalus, brain tumor) and/or evidence (CT or MRI results performed within the past 12 months or at screening) as the cause of dementia (provided that (Excluding lacunar cerebral infarction with a diameter of less than 1 cm in the area judged not to be related to cognitive function)

3. 3 = New Rating Scale for ARWMC (Age-Related White Matter Changes) score within 12 months of screening

4. Myocardial infarction, unstable angina pectoris, orthostatic hypotension or unexplained syncope within 12 months of screening, hospitalization for arrhythmia, or moderate to severe congestive heart failure (NYHA class III or IV), clinically Patients with significant structural heart disease (valvular disease, hypertrophic cardiomyopathy)

5. Serious mental disorders such as severe depression, schizophrenia, alcoholism, and drug dependence

6. History of malignant tumor within 5 years of screening. (However, enrollment is allowed if any of the following applies:)

• More than 5 years since completion of treatment for tumor

• Basal cell carcinoma, squamous cell carcinoma of the skin, or prostate cancer

7. Genetic problems such as galactose intolerance, lapp lactase deficiency or glucose galactose malabsorption

8. Gastrointestinal diseases (inflammatory bowel disease, etc.) that may affect the absorption of clinical investigational drugs

9. Administration of other dementia treatments (galantamine, rivastigmine, memantine) than donepezil within 3 months of screening

10. Administration of brain function improving drugs (citicoline, oxiracetam, piracetam, choline alfoscerate, Nicergoline, Nimodipine, ginko-biloba, acetyl-l carnitine, etc.) within 1 month of screening

11. Administration of dementia treatments, brain function improving agents, central nervous system stimulants, anticholinergics, tricyclic antidepressants, classic antipsychotics, and hypnotics (excluding short-acting hypnotics) other than experimental drugs during trial period

12. Administration of atypical antipsychotics, anxiolytics, antidepressants (except tricyclic antidepressants), thyroid hormones, short-acting hypnotics, hormone replacement therapy, vitamin E, vitamin B12 supplements, antiparkinsonian drugs, and cholinergic drugs during trial period (However, enrollment is allowed if all of the following apply:)

• Administration without any changes in dosage within 2 months of randomization

• Administration without any changes in dosage during trial period

• except for PRN drugs

13. Hypersensitivity to clinical investigational drugs (choline alfoscerate, donepezil), its components, or piperidine derivatives

14. Possibility of dementia due to abnormalities in vitamin B12, folic acid, and thyroid stimulating hormone (TSH) levels

15. Abnormalities in blood tests at screening:

• Liver dysfunction: AST or ALT = 3 times the upper limit of normal range

• Renal dysfunction: Creatinine clearance* < 25 mL/min/1.73 m2

*MDRD Formula Creatinine clearance (mL/min/1.73m2)= 175 × {serum Creatinine (mg/dL)}- 1.154 × (Age)-0.203 × 0.742 (for female only)

16. Uncontrolled hypertension (SBP>180 mmHg)

17. Illitera

18. Pregnancy and lactation

19. In case of a woman, a patient who does not fall under any of the following:

• Menopause for at least 2 years at time of screening

• Contraceptive through surgical methods

20. Deemed inappropriate for enrollment by the investigator for other reasons <Randomization Exclusion Criteria>

1) Abnormalities in blood tests at time of randomization

• Liver dysfunction: AST or ALT = 3 times the upper limit of normal range

• Renal dysfunction: Creatinine clearance* < 25 mL/min/1.73 m2 *MDRD Formula Creatinine clearance (mL/min/1.73m2)= 175 × {serum Creatinine (mg/dL)}- 1.154 × (Age)-0.203 × 0.742 (for female only) 2) Uncontrolled hypertension (SBP>180 mmHg) at the time of randomization 3) Administration of other investigational drugs within the past 3 months from the time of randomization 4) Deemed inappropriate for enrollment by the investigator for other reasons

Related Conditions & MeSH terms

• Alzheimer Disease

Intervention

Drug:
• Choline Alfoscerate 400mg
Oral administration
• Placebo
Oral administration

Locations

Country	Name	City	State
Korea, Republic of	Changwon Fatima Hospital	Changwon
Korea, Republic of	Gachon University Gil Medical Center	Incheon
Korea, Republic of	CHA Bundang Medical Center	Seongnam
Korea, Republic of	The Catholic University of Korea Seoul ST.MARY'S Hospital	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Daewoong Bio Inc.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in ADAS-Cog scores	ADAS-cog change at 12 and 24 weeks from baseline; Changes in ADAS-Cog scores at 48 weeks from baseline	48 weeks from baseline
Secondary	Changes in ADAS-Cog scores	Changes in ADAS-Cog scores at 12, 24 weeks from baseline	Time Frame: 12, 24 weeks from baseline
Secondary	Changes in ADCOMS scores	Changes in ADCOMS scores at 12, 24 and 48 weeks from baseline	12, 24, and 48 weeks from baseline
Secondary	Changes in K-IADL scores	Changes in K-IADL scores at 12, 24 and 48 weeks from baseline	12, 24, and 48 weeks from baseline
Secondary	Changes in CDR-SB scores	Changes in CDR-SB scores at 12, 24 and 48 weeks from baseline	12, 24, and 48 weeks from baseline
Secondary	Changes in K-MMSE-2 scores	Changes in K-MMSE-2 scores at 12, 24 and 48 weeks from baseline	12, 24, and 48 weeks from baseline